Analyst consensus rating
Aligos Therapeutics, Inc. Analyst Consensus Rating
ALGS analyst consensus rating, coverage count and price target evidence.
Direct answer
Aligos Therapeutics, Inc.'s consensus rating is Strong Buy.
7 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $56.29.
Forecast evidence checked August 13, 2026.
Get free Aligos Therapeutics, Inc. email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $7.00
- Average price target
- $56.29
- High price target
- $175.00
- Low price target
- $20.00
- Target upside
- +704.1%
- Consensus rating
- Strong Buy
- Analysts
- 7
- Evidence date
- August 13, 2026
- Valid through
- August 20, 2026